Journal article
Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada
Abstract
INTRODUCTION: There have been significant advances in systemic therapies for metastatic renal cell carcinoma (mRCC). There are currently 11 drugs approved by Health Canada: sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, nivolumab, ipilimumab, cabozantinib, lenvatinib, and pembrolizumab. These novel medications have dramatically altered the prognosis and patient experience. Despite proven benefits and recommendations for …
Authors
Jackson EB; Hotte SJ
Journal
Canadian Urological Association Journal, Vol. 16, No. 11, pp. e516–e522
Publisher
Canadian Urological Association Journal
Publication Date
November 2022
DOI
10.5489/cuaj.7846
ISSN
1911-6470